Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Jonathan

Barker

,

MD

Professor of Medical Dermatology
St John’s Institute of Dermatology, King’s College London
London
,
United Kingdom
Councilor Since: January 1, 2015
IPC Councilor Emeritus
Request an Update
Professor Jonathan Barker is a Professor of Medical Dermatology at St. John’s Institute of Dermatology, King’s College London, and an honorary consultant dermatologist at Guy’s and St. Thomas’s Hospitals specializing in complex hospital-based medical dermatology. Professor Barker is the immediate past President of the International Psoriasis Council having previously been a Board member and Chair of the Scientific Committee. He is a principal investigator in national and international consortia using genetic and multi-omic approaches to discover causal disease mechanisms, new drug targets, and biomarkers of disease subtypes and outcomes to therapeutic interventions. These are being applied to important chronic skin diseases such as psoriasis, acne, and eczema. Professor Barker has published over 300 peer-reviewed papers and authored and edited several books including the latest (10th) edition of Rook’s Textbook of Dermatology. Highly cited publications include those in The Lancet, Nature Genetics, and the New England Journal of Medicine. Professor Barker was Head of the Department at the Institute of Dermatology from 2002-2018 and a course director of the Institute’s MSc Clinical Dermatology for overseas graduates. He is a past President of the European Dermatology Forum and the European Society for Dermatological Research. He is an honorary overseas member of several national dermatological associations including Denmark, France, Germany, Japan, and the USA.
Last Updated:
05/13/2024

Languages Spoken

English
Recent publications

Featured

Blog

Focus on Psoriasis: A Report from the 33rd Annual European Academy of Dermatology and Venereology (EADV) Congress.

The 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…

Read More

Event

Psoriasis: From Gene to Clinic International Congress.

10TH INTERNATIONAL CONGRESS | LONDON, UNITED KINGDOM.

December 5, 2024
Learn More or Register

Page

International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International…

Generalized pustular psoriasis(GPP)lacks internationally accepted definitions and diagnostic criteria, impeding timely…

View Report

Event

Symposium: The Complete Guide to GPP: From Immunology to Treatment Goals.

26TH REGIONAL CONFERENCE OF DERMATOLOGY (RCD) | KUALA LUMPUR, MALAYSIA Program chairs: Siew Eng Choon, Malaysia and…

October 4, 2024
Learn More or Register

Event

Symposium: Optimizing the Management of Plaque Psoriasis: Insights from Experts.

26TH REGIONAL CONFERENCE OF DERMATOLOGY (RCD) | KUALA LUMPUR, MALAYSIA Program chairs: Siew Eng Choon, Malaysia and…

October 3, 2024
Learn More or Register

Blog

Focus on Psoriasis: A Report from the 2022 IPC Think Tank - Miami.

Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank…

Read More

PDF

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN).

Experts worldwide report on their experiences and deliver insight into the latest results and clinical studies. The…

View Report

Blog

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN)…

The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 –…

Read More

PDF

Focus on Psoriasis – A Report from the 2021 Hybrid Gene to Clinic Congress.

View Report

Blog

World Psoriasis Day.

Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients…

Read More

Blog

2020 Virtual Think Tank Meeting Report.

Held virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100…

Read More

PDF

Recategorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council.

View Report

PDF

Exome-wide Association Study Reveals Novel Psoriasis Susceptibility Locus at TNFSF15 and Rare Protective Alleles in…

View Report

PDF

Improving Clinical Trial Design in Psoriasis: Perspectives from the Global Dermatology Community.

View Report

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026